vs
Pacira BioSciences, Inc.（PCRX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是Pacira BioSciences, Inc.的1.1倍（$188.3M vs $177.4M），BRC Group Holdings, Inc.净利率更高（47.9% vs 1.6%，领先46.3%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -21.9%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -15.4%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
PCRX vs RILY — 直观对比
营收规模更大
RILY
是对方的1.1倍
$177.4M
营收增速更快
PCRX
高出26.9%
-21.9%
净利率更高
RILY
高出46.3%
1.6%
两年增速更快
PCRX
近两年复合增速
-15.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $188.3M |
| 净利润 | $2.9M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 3.9% | 32.3% |
| 净利率 | 1.6% | 47.9% |
| 营收同比 | 5.0% | -21.9% |
| 净利润同比 | — | 1710.8% |
| 每股收益（稀释后） | $0.07 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRILY
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $188.3M | ||
| Q3 25 | $179.5M | $215.3M | ||
| Q2 25 | $181.1M | $188.2M | ||
| Q1 25 | $168.9M | $197.2M | ||
| Q4 24 | $187.3M | $241.0M | ||
| Q3 24 | $168.6M | $225.5M | ||
| Q2 24 | $178.0M | $256.0M |
净利润PCRXRILY
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $90.3M | ||
| Q3 25 | $5.4M | $91.1M | ||
| Q2 25 | $-4.8M | $139.5M | ||
| Q1 25 | $4.8M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-143.5M | $-284.4M | ||
| Q2 24 | $18.9M | $-433.6M |
毛利率PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 79.5% | ||
| Q3 25 | 80.9% | 83.7% | ||
| Q2 25 | 77.4% | 81.3% | ||
| Q1 25 | 79.7% | 81.4% | ||
| Q4 24 | 78.7% | 79.8% | ||
| Q3 24 | 76.9% | 82.1% | ||
| Q2 24 | 75.1% | 84.5% |
营业利润率PCRXRILY
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 32.3% | ||
| Q3 25 | 3.5% | 30.4% | ||
| Q2 25 | 4.7% | 5.7% | ||
| Q1 25 | 1.2% | -31.2% | ||
| Q4 24 | 13.2% | -69.2% | ||
| Q3 24 | -82.8% | -36.4% | ||
| Q2 24 | 15.9% | -90.8% |
净利率PCRXRILY
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 47.9% | ||
| Q3 25 | 3.0% | 42.3% | ||
| Q2 25 | -2.7% | 74.1% | ||
| Q1 25 | 2.8% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -85.1% | -126.1% | ||
| Q2 24 | 10.6% | -169.4% |
每股收益（稀释后）PCRXRILY
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $2.78 | ||
| Q3 25 | $0.12 | $2.91 | ||
| Q2 25 | $-0.11 | $4.50 | ||
| Q1 25 | $0.10 | $-0.39 | ||
| Q4 24 | $0.38 | $-0.01 | ||
| Q3 24 | $-3.11 | $-9.39 | ||
| Q2 24 | $0.39 | $-14.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $653.9M | $-171.5M |
| 总资产 | $1.2B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRILY
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $226.6M | ||
| Q3 25 | $246.3M | $184.2M | ||
| Q2 25 | $445.9M | $267.4M | ||
| Q1 25 | $493.6M | $138.3M | ||
| Q4 24 | $484.6M | $146.9M | ||
| Q3 24 | $453.8M | $159.2M | ||
| Q2 24 | $404.2M | $236.9M |
总债务PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $1.4B | ||
| Q3 25 | $376.7M | $1.3B | ||
| Q2 25 | $580.5M | $1.3B | ||
| Q1 25 | $583.4M | $1.4B | ||
| Q4 24 | $585.3M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXRILY
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-171.5M | ||
| Q3 25 | $727.2M | $-260.5M | ||
| Q2 25 | $757.8M | $-351.7M | ||
| Q1 25 | $798.5M | $-496.8M | ||
| Q4 24 | $778.3M | $-488.2M | ||
| Q3 24 | $749.6M | $-497.6M | ||
| Q2 24 | $879.3M | $-218.3M |
总资产PCRXRILY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B |
负债/权益比PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $26.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $26.2M | ||
| Q3 25 | $60.8M | $-60.6M | ||
| Q2 25 | $12.0M | $-25.6M | ||
| Q1 25 | $35.5M | $184.0K | ||
| Q4 24 | $33.1M | $-2.7M | ||
| Q3 24 | $53.9M | $19.5M | ||
| Q2 24 | $53.2M | $111.5M |
自由现金流PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — |
自由现金流率PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — |
资本支出强度PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — |
现金转化率PCRXRILY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | 11.20× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
